Get notified when SCTX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — Substantial doubt about ability to continue as a going concern remains, with cash and accumulated deficit figures unchanged from the prior filing.
SCTX Scribe Therapeutics, Inc. S-1/A

Scribe Therapeutics finalizes IPO terms: $14.00 midpoint, $96.2M net proceeds, cash runway to H1 2029

Filed July 20, 2026 · Compared to S-1/A Jul 10, 2026 · ~1 min read

Key Changes

  • high

    IPO priced at $14.00 midpoint; net proceeds estimated at $96.2M (or $110.2M if underwriters' option fully exercised), including a $7.5M concurrent private placement from Sanofi.

    Use of Proceeds verify on EDGAR →
  • high

    Cash runway extended into first half of 2029, based on existing cash plus net proceeds from the offering and concurrent private placement.

    MD&A: Liquidity verify on EDGAR →
  • high

    New investors face immediate dilution of $7.92 per share at the $14.00 IPO price; pro forma net tangible book value per share is $6.08.

    Dilution verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade SCTX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify